01-04-2009 | Clinical Trials Report
The role of gemtuzumab ozogamicin in combination chemotherapy regimens for primary resistant or relapsed acute myeloid leukemia
Published in: Current Hematologic Malignancy Reports | Issue 2/2009
Login to get access